BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim SG, Agcaoili J, De Souza NNA, Chan E. Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. J Viral Hepat. 2019;26:803-817. [PMID: 30801899 DOI: 10.1111/jvh.13085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Hui RW, Mak L, Cheung K, Fung J, Seto W, Yuen M. Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00590-4] [Reference Citation Analysis]
2 Zhang Y, Guo M, Zhang X, Zhang N, Zhu P, Wang H. Multiple optimizations of recombinant plasmid for improving expression of Hepatitis B core antigen in Escherichia coli. Protein Expr Purif 2022;:106127. [PMID: 35660658 DOI: 10.1016/j.pep.2022.106127] [Reference Citation Analysis]
3 Ongaro M, Negro F. Hépatite B et C: une mise à jour sur lʼhépatite virale chronique. Schweiz Gastroenterol 2022;3:19-27. [DOI: 10.1007/s43472-022-00062-6] [Reference Citation Analysis]
4 Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol 2022; 28(3): 290-309 [DOI: 10.3748/wjg.v28.i3.290] [Reference Citation Analysis]
5 Melief CJ, Wiekmeijer A, van der Gracht ET. Therapeutic cancer vaccines targeting viral antigens. Cancer Vaccines as Immunotherapy of Cancer 2022. [DOI: 10.1016/b978-0-12-823901-8.00013-3] [Reference Citation Analysis]
6 Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 De Pooter D, Van Gulck E, Chen A, Evans CF, Neefs JM, Horton H, Boden D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines (Basel) 2021;9:969. [PMID: 34579206 DOI: 10.3390/vaccines9090969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. WJGPT 2021;12:56-78. [DOI: 10.4292/wjg.v12.i4.56] [Reference Citation Analysis]
9 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(4): 56-78 [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dusheiko G. Will we need novel combinations to cure HBV infection? Liver Int 2020;40 Suppl 1:35-42. [PMID: 32077595 DOI: 10.1111/liv.14371] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
11 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Xiao D, Wang J, Chen Z, Jin X, Xie Y, Yan D, Yang J. Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects. BMC Infect Dis 2021;21:111. [PMID: 33485302 DOI: 10.1186/s12879-021-05816-2] [Reference Citation Analysis]
13 Ward JW. Hepatitis B Vaccines. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lee HW, Lee JS, Ahn SH. Hepatitis B Virus Cure: Targets and Future Therapies. Int J Mol Sci 2020;22:E213. [PMID: 33379331 DOI: 10.3390/ijms22010213] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
15 Clemente MG, Antonucci R, Sotgiu G, Dettori M, Piana A, Vajro P. Present and future management of viral hepatitis B and C in children. Clinics and Research in Hepatology and Gastroenterology 2020;44:801-9. [DOI: 10.1016/j.clinre.2020.02.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
18 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 115] [Cited by in F6Publishing: 93] [Article Influence: 57.5] [Reference Citation Analysis]
19 Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: an update. Future Virology 2020;15:35-51. [DOI: 10.2217/fvl-2019-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother 2020;16:251-68. [PMID: 31809638 DOI: 10.1080/21645515.2019.1689745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2019. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
22 Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. [PMID: 31548710 DOI: 10.1038/s41575-019-0196-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 19.7] [Reference Citation Analysis]
23 Kosinska AD, Moeed A, Kallin N, Festag J, Su J, Steiger K, Michel ML, Protzer U, Knolle PA. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Sci Rep 2019;9:10808. [PMID: 31346211 DOI: 10.1038/s41598-019-47149-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
24 Lopatin U. Drugs in the Pipeline for HBV. Clin Liver Dis. 2019;23:535-555. [PMID: 31266626 DOI: 10.1016/j.cld.2019.04.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]